Skip to main content
Top
Published in: Journal of Gastroenterology 3/2018

Open Access 01-03-2018 | Special Article

Evidence-based clinical practice guidelines for inflammatory bowel disease

Authors: Katsuyoshi Matsuoka, Taku Kobayashi, Fumiaki Ueno, Toshiyuki Matsui, Fumihito Hirai, Nagamu Inoue, Jun Kato, Kenji Kobayashi, Kiyonori Kobayashi, Kazutaka Koganei, Reiko Kunisaki, Satoshi Motoya, Masakazu Nagahori, Hiroshi Nakase, Fumio Omata, Masayuki Saruta, Toshiaki Watanabe, Toshiaki Tanaka, Takanori Kanai, Yoshinori Noguchi, Ken-ichi Takahashi, Kenji Watanabe, Toshifumi Hibi, Yasuo Suzuki, Mamoru Watanabe, Kentaro Sugano, Tooru Shimosegawa

Published in: Journal of Gastroenterology | Issue 3/2018

Login to get access

Abstract

Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn’s disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23 (quiz 24. Epub 2010/01/14).PubMedCrossRef Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23 (quiz 24. Epub 2010/01/14).PubMedCrossRef
2.
go back to reference Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465–83 (quiz 4, 84. Epub 2009/01/29).PubMedCrossRef Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465–83 (quiz 4, 84. Epub 2009/01/29).PubMedCrossRef
4.
go back to reference Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24 (Epub 2012/11/07).PubMedPubMedCentralCrossRef Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24 (Epub 2012/11/07).PubMedPubMedCentralCrossRef
5.
go back to reference Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–63 (Epub 2005/01/29).PubMedCrossRef Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–63 (Epub 2005/01/29).PubMedCrossRef
6.
go back to reference Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–71 (Epub 2006/11/24).PubMedCrossRef Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–71 (Epub 2006/11/24).PubMedCrossRef
7.
go back to reference Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol. 2000;95(1):171–6 (Epub 2000/01/19).PubMedCrossRef Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol. 2000;95(1):171–6 (Epub 2000/01/19).PubMedCrossRef
8.
go back to reference Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400 (Epub 2008/08/08).PubMedCrossRef Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400 (Epub 2008/08/08).PubMedCrossRef
9.
go back to reference Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2000;95(8):1949–54 (Epub 2000/08/19).PubMedCrossRef Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2000;95(8):1949–54 (Epub 2000/08/19).PubMedCrossRef
10.
go back to reference Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103(11):2925–31 (Epub 2008/09/09).PubMedCrossRef Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103(11):2925–31 (Epub 2008/09/09).PubMedCrossRef
11.
go back to reference Munakata A. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1998. p. 96–9. Munakata A. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1998. p. 96–9.
13.
14.
go back to reference Matsui T. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2010. p. 484–8. Matsui T. Draft revision of diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2010. p. 484–8.
15.
go back to reference Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8–15 (Epub 2000/03/04).PubMedCrossRef Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8–15 (Epub 2000/03/04).PubMedCrossRef
16.
go back to reference Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44 (Epub 1976/03/11).PubMed Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44 (Epub 1976/03/11).PubMed
17.
go back to reference Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (Lond, Engl). 1980;1(8167):514 (Epub 1980/03/08).CrossRef Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (Lond, Engl). 1980;1(8167):514 (Epub 1980/03/08).CrossRef
18.
go back to reference Matsui T. Draft diagnostic criteria for Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 43–5. Matsui T. Draft diagnostic criteria for Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 43–5.
19.
go back to reference Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108(1):83–9 (Epub 2012/09/26).PubMedCrossRef Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108(1):83–9 (Epub 2012/09/26).PubMedCrossRef
20.
go back to reference Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13 (Epub 2000/09/15).PubMedPubMedCentralCrossRef Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13 (Epub 2000/09/15).PubMedPubMedCentralCrossRef
21.
go back to reference Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004;126(6):1561–73 (Epub 2004/05/29).PubMedCrossRef Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004;126(6):1561–73 (Epub 2004/05/29).PubMedCrossRef
22.
go back to reference Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607 (Epub 2011/04/06).PubMedCrossRef Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607 (Epub 2011/04/06).PubMedCrossRef
23.
go back to reference Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2(1):1–23 (Epub 2008/03/01).PubMedCrossRef Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2(1):1–23 (Epub 2008/03/01).PubMedCrossRef
24.
go back to reference Fukuchi T, Nakase H, Matsuura M, et al. Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohns Colitis. 2013;7(10):803–11 (Epub 2013/01/29).PubMedCrossRef Fukuchi T, Nakase H, Matsuura M, et al. Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohns Colitis. 2013;7(10):803–11 (Epub 2013/01/29).PubMedCrossRef
25.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9 (Epub 1987/12/24).PubMedCrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9 (Epub 1987/12/24).PubMedCrossRef
26.
go back to reference Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (Clin Res Ed). 1989;298(6666):82–6 (Epub 1989/01/14).CrossRef Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (Clin Res Ed). 1989;298(6666):82–6 (Epub 1989/01/14).CrossRef
27.
go back to reference Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9 (Epub 1989/07/01).PubMedPubMedCentralCrossRef Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9 (Epub 1989/07/01).PubMedPubMedCentralCrossRef
28.
go back to reference Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13(9):1100–5 (Epub 2007/05/18).PubMedCrossRef Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13(9):1100–5 (Epub 2007/05/18).PubMedCrossRef
29.
go back to reference Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92(1):181–5 (Epub 1987/01/01).PubMedCrossRef Pera A, Bellando P, Caldera D, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92(1):181–5 (Epub 1987/01/01).PubMedCrossRef
30.
go back to reference Witte AM, Veenendaal RA, Van Hogezand RA, et al. Crohn’s disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl. 1998;225:100–5 (Epub 1998/03/27).PubMed Witte AM, Veenendaal RA, Van Hogezand RA, et al. Crohn’s disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl. 1998;225:100–5 (Epub 1998/03/27).PubMed
31.
go back to reference Schmitz-Moormann P, Schag M. Histology of the lower intestinal tract in Crohn’s disease of children and adolescents. Multicentric Paediatric Crohn’s Disease Study. Pathol Res Pract. 1990;186(4):479–84 (Epub 1990/08/01).PubMedCrossRef Schmitz-Moormann P, Schag M. Histology of the lower intestinal tract in Crohn’s disease of children and adolescents. Multicentric Paediatric Crohn’s Disease Study. Pathol Res Pract. 1990;186(4):479–84 (Epub 1990/08/01).PubMedCrossRef
32.
go back to reference De Matos V, Russo PA, Cohen AB, Finkel Y. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46(4):392–8 (Epub 2008/03/28).PubMedCrossRef De Matos V, Russo PA, Cohen AB, Finkel Y. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46(4):392–8 (Epub 2008/03/28).PubMedCrossRef
33.
go back to reference Rubio CA, Orrego A, Nesi G, et al. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn’s colitis. J Clin Pathol. 2007;60(11):1268–72 (Epub 2007/02/13).PubMedPubMedCentralCrossRef Rubio CA, Orrego A, Nesi G, et al. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn’s colitis. J Clin Pathol. 2007;60(11):1268–72 (Epub 2007/02/13).PubMedPubMedCentralCrossRef
34.
go back to reference Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2010;105(6):1240–8 (quiz 9. Epub 2009/12/24).PubMedCrossRef Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2010;105(6):1240–8 (quiz 9. Epub 2009/12/24).PubMedCrossRef
35.
go back to reference Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009;41(7):618–37 (Epub 2009/07/10).PubMedCrossRef Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009;41(7):618–37 (Epub 2009/07/10).PubMedCrossRef
36.
go back to reference Matsui T. Draft diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2011. p. 479–83. Matsui T. Draft diagnostic criteria for ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2011. p. 479–83.
37.
go back to reference Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018 (Epub 2013/11/05).PubMedCrossRef Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018 (Epub 2013/11/05).PubMedCrossRef
38.
go back to reference Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556–85 (Epub 2013/04/16).PubMedCrossRef Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556–85 (Epub 2013/04/16).PubMedCrossRef
39.
go back to reference Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–90 (Epub 2012/10/09).PubMedCrossRef Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–90 (Epub 2012/10/09).PubMedCrossRef
40.
go back to reference Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247(1):64–79 (Epub 2008/03/29).PubMedCrossRef Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247(1):64–79 (Epub 2008/03/29).PubMedCrossRef
41.
go back to reference Hollerbach S, Geissler A, Schiegl H, et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol. 1998;33(11):1201–8 (Epub 1998/12/29).PubMedCrossRef Hollerbach S, Geissler A, Schiegl H, et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol. 1998;33(11):1201–8 (Epub 1998/12/29).PubMedCrossRef
42.
go back to reference Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43(10 Suppl):S85–93 (Epub 2000/10/29).PubMedCrossRef Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43(10 Suppl):S85–93 (Epub 2000/10/29).PubMedCrossRef
43.
go back to reference Hisabe T, Hirai F, Matsui T, et al. Evaluation of diagnostic criteria for Crohn’s disease in Japan. J Gastroenterol. 2014;49(1):93–9 (Epub 2013/04/03).PubMedCrossRef Hisabe T, Hirai F, Matsui T, et al. Evaluation of diagnostic criteria for Crohn’s disease in Japan. J Gastroenterol. 2014;49(1):93–9 (Epub 2013/04/03).PubMedCrossRef
44.
go back to reference Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27 (Epub 2010/12/03).PubMedCrossRef Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27 (Epub 2010/12/03).PubMedCrossRef
45.
go back to reference Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34(2):125–45 (Epub 2011/05/28).PubMedCrossRef Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34(2):125–45 (Epub 2011/05/28).PubMedCrossRef
46.
go back to reference Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255–66 (Epub 2008/06/03).PubMedCrossRef Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255–66 (Epub 2008/06/03).PubMedCrossRef
47.
go back to reference Giles E, Barclay AR, Chippington S, et al. Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2013;37(12):1121–31 (Epub 2013/05/04).PubMedCrossRef Giles E, Barclay AR, Chippington S, et al. Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2013;37(12):1121–31 (Epub 2013/05/04).PubMedCrossRef
48.
go back to reference Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology. 2009;251(3):751–61 (Epub 2009/03/12).PubMedCrossRef Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology. 2009;251(3):751–61 (Epub 2009/03/12).PubMedCrossRef
49.
go back to reference Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96(7):2113–6 (Epub 2001/07/27).PubMedCrossRef Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96(7):2113–6 (Epub 2001/07/27).PubMedCrossRef
50.
go back to reference Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23(12):1213–21 (Epub 2008/09/03).PubMedCrossRef Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23(12):1213–21 (Epub 2008/09/03).PubMedCrossRef
51.
go back to reference Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717–25 (Epub 2014/03/19).PubMedCrossRef Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717–25 (Epub 2014/03/19).PubMedCrossRef
52.
go back to reference Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123(3):707–13 (Epub 2002/08/29).PubMedCrossRef Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123(3):707–13 (Epub 2002/08/29).PubMedCrossRef
53.
go back to reference Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther. 2003;17(12):1451–7 (Epub 2003/06/26).PubMedCrossRef Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther. 2003;17(12):1451–7 (Epub 2003/06/26).PubMedCrossRef
54.
go back to reference Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis. 2009;15(5):734–41 (Epub 2008/12/11).PubMedCrossRef Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis. 2009;15(5):734–41 (Epub 2008/12/11).PubMedCrossRef
55.
go back to reference Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120(5):1093–9 (Epub 2001/03/27).PubMedCrossRef Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120(5):1093–9 (Epub 2001/03/27).PubMedCrossRef
56.
go back to reference Swanson GR, Sedghi S, Farhadi A, et al. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol (Fayettev, NY). 2010;44(3):223–8 (Epub 2010/08/05).CrossRef Swanson GR, Sedghi S, Farhadi A, et al. Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol (Fayettev, NY). 2010;44(3):223–8 (Epub 2010/08/05).CrossRef
57.
go back to reference Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167–76 (author reply 77. Epub 2011/11/24).PubMedCrossRef Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167–76 (author reply 77. Epub 2011/11/24).PubMedCrossRef
58.
go back to reference Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):Cd004115 (Epub 2010/01/22). Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):Cd004115 (Epub 2010/01/22).
59.
go back to reference Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:Cd004118 (Epub 2012/11/16).PubMed Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:Cd004118 (Epub 2012/11/16).PubMed
60.
go back to reference Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000543 (Epub 2012/10/19).PubMed Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000543 (Epub 2012/10/19).PubMed
61.
go back to reference Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000544 (Epub 2012/10/19).PubMed Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:Cd000544 (Epub 2012/10/19).PubMed
62.
go back to reference Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;(12):Cd008870 (Epub 2010/12/15). Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;(12):Cd008870 (Epub 2010/12/15).
63.
go back to reference Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2004;2(5):379–88 (Epub 2004/05/01). Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2004;2(5):379–88 (Epub 2004/05/01).
64.
go back to reference Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003715 (Epub 2005/01/28). Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003715 (Epub 2005/01/28).
65.
go back to reference Gordon M, Naidoo K, Thomas AG, Moss AC. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd008414 (Epub 2011/01/21). Gordon M, Naidoo K, Thomas AG, Moss AC. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd008414 (Epub 2011/01/21).
66.
go back to reference Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53 (Epub 2005/06/03).PubMedCrossRef Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53 (Epub 2005/06/03).PubMedCrossRef
67.
go back to reference O’Connor A, Packey CD, Akbari M, et al. Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2562–9 (Epub 2015/08/22).PubMedCrossRef O’Connor A, Packey CD, Akbari M, et al. Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2562–9 (Epub 2015/08/22).PubMedCrossRef
68.
go back to reference Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107(9):1298–304 (quiz 7, 305. Epub 2012/07/04).PubMedCrossRef Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107(9):1298–304 (quiz 7, 305. Epub 2012/07/04).PubMedCrossRef
69.
go back to reference Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–9 (quiz 600. Epub 2011/03/17).PubMedCrossRef Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–9 (quiz 600. Epub 2011/03/17).PubMedCrossRef
70.
go back to reference Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(2):Cd006792 (Epub 2008/04/22). Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(2):Cd006792 (Epub 2008/04/22).
71.
go back to reference Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):Cd000301 (Epub 2003/10/30). Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):Cd000301 (Epub 2003/10/30).
72.
go back to reference Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet (Lond, Engl). 1965;1(7378):188–9 (Epub 1965/01/23).CrossRef Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet (Lond, Engl). 1965;1(7378):188–9 (Epub 1965/01/23).CrossRef
73.
go back to reference Powell-Tuck J, Bown RL, Chambers TJ, et al. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263–70 (Epub 1981/01/01).PubMedCrossRef Powell-Tuck J, Bown RL, Chambers TJ, et al. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263–70 (Epub 1981/01/01).PubMedCrossRef
74.
go back to reference Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337–50 (Epub 2014/05/14).PubMedCrossRef Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337–50 (Epub 2014/05/14).PubMedCrossRef
75.
go back to reference Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;(6):Cd000296 (Epub 2015/06/04). Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;(6):Cd000296 (Epub 2015/06/04).
76.
go back to reference Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd002913 (Epub 2009/01/23). Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd002913 (Epub 2009/01/23).
77.
go back to reference Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):630–42 (Epub 2011/03/17).PubMedCrossRef Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):630–42 (Epub 2011/03/17).PubMedCrossRef
78.
go back to reference Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;(9):Cd000478 (Epub 2012/09/14). Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;(9):Cd000478 (Epub 2012/09/14).
79.
go back to reference Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd000067 (Epub 2009/01/23). Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):Cd000067 (Epub 2009/01/23).
80.
go back to reference Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(1):23–34 (quiz 5. Epub 2013/12/11).PubMedCrossRef Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(1):23–34 (quiz 5. Epub 2013/12/11).PubMedCrossRef
81.
go back to reference Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104(8):2089–96 (Epub 2009/07/02).PubMedCrossRef Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104(8):2089–96 (Epub 2009/07/02).PubMedCrossRef
82.
go back to reference Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;(4):Cd000545 (Epub 2013/05/02). Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;(4):Cd000545 (Epub 2013/05/02).
83.
go back to reference Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5 (Epub 2005/07/13).PubMedPubMedCentralCrossRef Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5 (Epub 2005/07/13).PubMedPubMedCentralCrossRef
84.
go back to reference Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (Lond, Engl). 2009;374(9701):1617–25 (Epub 2009/10/20).CrossRef Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (Lond, Engl). 2009;374(9701):1617–25 (Epub 2009/10/20).CrossRef
85.
go back to reference Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.e3 (Epub 2013/07/31). Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.e3 (Epub 2013/07/31).
86.
go back to reference Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8(1):31–44 (Epub 2013/06/01).PubMedCrossRef Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8(1):31–44 (Epub 2013/06/01).PubMedCrossRef
87.
go back to reference Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783–800 (Epub 2008/06/19).PubMedCrossRef Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103(7):1783–800 (Epub 2008/06/19).PubMedCrossRef
88.
go back to reference Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;(3):Cd007216 (Epub 2008/07/23). Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;(3):Cd007216 (Epub 2008/07/23).
89.
go back to reference Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18(5):803–8 (Epub 2011/09/03).PubMedCrossRef Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18(5):803–8 (Epub 2011/09/03).PubMedCrossRef
90.
go back to reference Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;(1):Cd004277 (Epub 2005/01/28). Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;(1):Cd004277 (Epub 2005/01/28).
91.
go back to reference Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (Lond, Engl). 2012;380(9857):1909–15 (Epub 2012/10/16).CrossRef Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (Lond, Engl). 2012;380(9857):1909–15 (Epub 2012/10/16).CrossRef
92.
go back to reference Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608 (Epub 2012/08/22).PubMedCrossRef Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608 (Epub 2012/08/22).PubMedCrossRef
93.
go back to reference Morikawa K, Watabe H, Araake M, et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996;40(6):1366–70 (Epub 1996/06/01).PubMedPubMedCentral Morikawa K, Watabe H, Araake M, et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996;40(6):1366–70 (Epub 1996/06/01).PubMedPubMedCentral
94.
go back to reference Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73 (Epub 2011/03/17).PubMedCrossRef Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73 (Epub 2011/03/17).PubMedCrossRef
95.
go back to reference Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–6 (Epub 2012/12/12).PubMedPubMedCentralCrossRef Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–6 (Epub 2012/12/12).PubMedPubMedCentralCrossRef
96.
go back to reference Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52(11):2920–5 (Epub 2007/04/07).PubMedCrossRef Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52(11):2920–5 (Epub 2007/04/07).PubMedCrossRef
97.
go back to reference Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet (Lond, Engl). 1974;1(7866):1067–70 (Epub 1974/06/01).CrossRef Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet (Lond, Engl). 1974;1(7866):1067–70 (Epub 1974/06/01).CrossRef
98.
go back to reference Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105(8):1820–9 (Epub 2010/03/11).PubMedCrossRef Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105(8):1820–9 (Epub 2010/03/11).PubMedCrossRef
99.
go back to reference Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;(6):Cd001176 (Epub 2010/06/18). Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;(6):Cd001176 (Epub 2010/06/18).
100.
go back to reference Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;(12):Cd007443 (Epub 2011/12/14). Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;(12):Cd007443 (Epub 2011/12/14).
101.
go back to reference Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35 (Epub 2013/11/28).PubMedCrossRef Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35 (Epub 2013/11/28).PubMedCrossRef
102.
go back to reference Sang LX, Chang B, Zhang WL, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol. 2010;16(15):1908–15 (Epub 2010/04/17).PubMedPubMedCentralCrossRef Sang LX, Chang B, Zhang WL, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol. 2010;16(15):1908–15 (Epub 2010/04/17).PubMedPubMedCentralCrossRef
103.
go back to reference Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59 (quiz 60. Epub 2011/03/17).PubMedCrossRef Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59 (quiz 60. Epub 2011/03/17).PubMedCrossRef
104.
go back to reference Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1-3 (Epub 2011/11/09). Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1-3 (Epub 2011/11/09).
105.
go back to reference Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2015;49(8):675–82 (Epub 2014/11/13).PubMedCrossRef Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2015;49(8):675–82 (Epub 2014/11/13).PubMedCrossRef
106.
go back to reference Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38 (Epub 2007/05/02).PubMedCrossRef Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38 (Epub 2007/05/02).PubMedCrossRef
107.
go back to reference Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95 (Epub 2010/04/16).PubMedCrossRef Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95 (Epub 2010/04/16).PubMedCrossRef
108.
go back to reference Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.e5 (quiz e31. Epub 2011/09/29). Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.e5 (quiz e31. Epub 2011/09/29).
109.
go back to reference Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–92 (Epub 2014/06/22).PubMedCrossRef Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–92 (Epub 2014/06/22).PubMedCrossRef
110.
go back to reference Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–92 (Epub 2005/06/30).PubMedCrossRef Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–92 (Epub 2005/06/30).PubMedCrossRef
111.
go back to reference Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–6 (Epub 2012/02/22).PubMedCrossRef Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–6 (Epub 2012/02/22).PubMedCrossRef
112.
go back to reference Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1–58 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1–58
113.
go back to reference Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22 (Epub 2015/12/08).PubMedCrossRef Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22 (Epub 2015/12/08).PubMedCrossRef
114.
go back to reference Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterological Assoc. 2006;4(5):621–30 (Epub 2006/05/09). Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterological Assoc. 2006;4(5):621–30 (Epub 2006/05/09).
115.
go back to reference Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23 (Epub 2014/01/08).PubMedCrossRef Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212–23 (Epub 2014/01/08).PubMedCrossRef
116.
go back to reference Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepat Off Clin Pract J Am Gastroenterol Assoc. 2009;7(8):874–81 (Epub 2009/06/30). Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepat Off Clin Pract J Am Gastroenterol Assoc. 2009;7(8):874–81 (Epub 2009/06/30).
117.
go back to reference Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):36–41.e1 (Epub 2010/10/05). Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):36–41.e1 (Epub 2010/10/05).
118.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76 (Epub 2005/12/13).PubMedCrossRef Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76 (Epub 2005/12/13).PubMedCrossRef
119.
go back to reference Lochs H, Dejong C, Hammarqvist F, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr (Edinb, Scotl). 2006;25(2):260–74 (Epub 2006/05/16).CrossRef Lochs H, Dejong C, Hammarqvist F, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr (Edinb, Scotl). 2006;25(2):260–74 (Epub 2006/05/16).CrossRef
120.
go back to reference Jowett SL, Seal CJ, Phillips E, et al. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr (Edinb, Scotl). 2004;23(2):161–70 (Epub 2004/03/20).CrossRef Jowett SL, Seal CJ, Phillips E, et al. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr (Edinb, Scotl). 2004;23(2):161–70 (Epub 2004/03/20).CrossRef
121.
go back to reference Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(1):Cd000542 (Epub 2007/01/27). Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(1):Cd000542 (Epub 2007/01/27).
122.
go back to reference Okada M, Yao T, Yamamoto T, et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990;37(1):72–80 (Epub 1990/02/01).PubMed Okada M, Yao T, Yamamoto T, et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990;37(1):72–80 (Epub 1990/02/01).PubMed
123.
go back to reference Diagnostic criteria for and management of ulcerative colitis and Crohn’ disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014. Diagnostic criteria for and management of ulcerative colitis and Crohn’ disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014.
124.
go back to reference Messori A, Trallori G, D’Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn’s disease: a meta-analysis. Scand J Gastroenterol. 1996;31(3):267–72 (Epub 1996/03/01).PubMedCrossRef Messori A, Trallori G, D’Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn’s disease: a meta-analysis. Scand J Gastroenterol. 1996;31(3):267–72 (Epub 1996/03/01).PubMedCrossRef
125.
go back to reference Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).PubMedCrossRef Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).PubMedCrossRef
126.
go back to reference Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2000;32(9):769–74 (Epub 2001/02/24). Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2000;32(9):769–74 (Epub 2001/02/24).
127.
go back to reference Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(3):Cd005984 (Epub 2007/07/20). Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;(3):Cd005984 (Epub 2007/07/20).
128.
go back to reference Matsui T, Ueki M, Yamada M, et al. Indications and options of nutritional treatment for Crohn’s disease. A comparison of elemental and polymeric diets. J Gastroenterol. 1995;30(Suppl 8):95–7 (Epub 1995/11/01).PubMed Matsui T, Ueki M, Yamada M, et al. Indications and options of nutritional treatment for Crohn’s disease. A comparison of elemental and polymeric diets. J Gastroenterol. 1995;30(Suppl 8):95–7 (Epub 1995/11/01).PubMed
129.
go back to reference Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400–9 (Epub 2008/07/08).PubMedCrossRef Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400–9 (Epub 2008/07/08).PubMedCrossRef
130.
go back to reference Zhu M, Xu X, Nie F, et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis. 2011;26(8):999–1007 (Epub 2011/04/09).PubMedCrossRef Zhu M, Xu X, Nie F, et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis. 2011;26(8):999–1007 (Epub 2011/04/09).PubMedCrossRef
131.
go back to reference Sigurbjornsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5(9):509–16 (Epub 2008/07/31).PubMedCrossRef Sigurbjornsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5(9):509–16 (Epub 2008/07/31).PubMedCrossRef
132.
go back to reference Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104(12):2990–5 (Epub 2009/09/03).PubMedCrossRef Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104(12):2990–5 (Epub 2009/09/03).PubMedCrossRef
133.
go back to reference Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol. 2004;39(12):1158–64 (Epub 2004/12/29).PubMedCrossRef Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol. 2004;39(12):1158–64 (Epub 2004/12/29).PubMedCrossRef
134.
go back to reference Fukunaga K, Yokoyama Y, Kamokozuru K, et al. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6(4):427–33 (Epub 2012/11/22).PubMedPubMedCentralCrossRef Fukunaga K, Yokoyama Y, Kamokozuru K, et al. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6(4):427–33 (Epub 2012/11/22).PubMedPubMedCentralCrossRef
135.
go back to reference Tate D, Cairnes V, Valori R, et al. First successful use of leukocyte apheresis as maintenance therapy for Crohn’s disease in the United Kingdom. J Clin Apher. 2014;29(3):181–2 (Epub 2013/11/19).PubMedCrossRef Tate D, Cairnes V, Valori R, et al. First successful use of leukocyte apheresis as maintenance therapy for Crohn’s disease in the United Kingdom. J Clin Apher. 2014;29(3):181–2 (Epub 2013/11/19).PubMedCrossRef
136.
go back to reference Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030 (Epub 2012/10/09).PubMedCrossRef Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030 (Epub 2012/10/09).PubMedCrossRef
137.
go back to reference Guidelines for surgical treatment of ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014. Guidelines for surgical treatment of ulcerative colitis. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014.
138.
go back to reference Heikens JT, de Vries J, van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis Off J Assoc Coloproctol Gt Br Irel. 2012;14(5):536–44 (Epub 2010/12/24). Heikens JT, de Vries J, van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis Off J Assoc Coloproctol Gt Br Irel. 2012;14(5):536–44 (Epub 2010/12/24).
139.
go back to reference Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012;55(11):1131–7 (Epub 2012/10/10).PubMedCrossRef Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012;55(11):1131–7 (Epub 2012/10/10).PubMedCrossRef
140.
go back to reference da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010;97(1):65–9 (Epub 2009/12/17). da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010;97(1):65–9 (Epub 2009/12/17).
141.
go back to reference Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg (Chic, Ill: 1960). 1998;133(8):826–32 (Epub 1998/08/26). Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg (Chic, Ill: 1960). 1998;133(8):826–32 (Epub 1998/08/26).
142.
go back to reference Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn’s disease: influence of surgical operation—a prospective trial. Dig Dis Sci. 1999;44(5):932–8 (Epub 1999/05/11).PubMedCrossRef Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn’s disease: influence of surgical operation—a prospective trial. Dig Dis Sci. 1999;44(5):932–8 (Epub 1999/05/11).PubMedCrossRef
143.
go back to reference Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679–85 (Epub 2013/01/10).PubMedCrossRef Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679–85 (Epub 2013/01/10).PubMedCrossRef
144.
go back to reference de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(11):972–80 (Epub 2011/08/03). de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(11):972–80 (Epub 2011/08/03).
145.
go back to reference Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn’s disease: a meta-analysis. Dis Colon Rectum. 2007;50(5):576–85 (Epub 2007/03/24).PubMedCrossRef Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn’s disease: a meta-analysis. Dis Colon Rectum. 2007;50(5):576–85 (Epub 2007/03/24).PubMedCrossRef
146.
go back to reference Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49(9):1293–306 (Epub 2006/07/11).PubMedCrossRef Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49(9):1293–306 (Epub 2006/07/11).PubMedCrossRef
147.
go back to reference Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007;50(8):1128–38 (Epub 2007/06/26).PubMedCrossRef Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007;50(8):1128–38 (Epub 2007/06/26).PubMedCrossRef
148.
go back to reference Resegotti A, Astegiano M, Farina EC, et al. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn’s disease surgery. Dis Colon Rectum. 2005;48(3):464–8 (Epub 2005/02/19).PubMedCrossRef Resegotti A, Astegiano M, Farina EC, et al. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn’s disease surgery. Dis Colon Rectum. 2005;48(3):464–8 (Epub 2005/02/19).PubMedCrossRef
149.
go back to reference Higashi D, Futami K, Egawa Y, et al. Prevention and countermeasures for suture failure in patients with Crohn’s disease. J Jpn Soc Coloproctol. 2009;62(10):818–22. Higashi D, Futami K, Egawa Y, et al. Prevention and countermeasures for suture failure in patients with Crohn’s disease. J Jpn Soc Coloproctol. 2009;62(10):818–22.
150.
go back to reference Watanabe K, Sasaki I, Fukushima K, et al. Long-term incidence and characteristics of intestinal failure in Crohn’s disease: a multicenter study. J Gastroenterol. 2014;49(2):231–8 (Epub 2013/04/09).PubMedCrossRef Watanabe K, Sasaki I, Fukushima K, et al. Long-term incidence and characteristics of intestinal failure in Crohn’s disease: a multicenter study. J Gastroenterol. 2014;49(2):231–8 (Epub 2013/04/09).PubMedCrossRef
151.
go back to reference Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–16 (Epub 2011/03/17).PubMedCrossRef Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–16 (Epub 2011/03/17).PubMedCrossRef
152.
go back to reference Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76 (Epub 2000/05/16).PubMedCrossRef Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76 (Epub 2000/05/16).PubMedCrossRef
153.
go back to reference Regueiro M, Loftus EV Jr, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006;12(10):972–8 (Epub 2006/10/03).PubMedCrossRef Regueiro M, Loftus EV Jr, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006;12(10):972–8 (Epub 2006/10/03).PubMedCrossRef
154.
go back to reference Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12(10):979–94 (Epub 2006/10/03).PubMedCrossRef Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12(10):979–94 (Epub 2006/10/03).PubMedCrossRef
155.
go back to reference Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775–81 (Epub 1997/06/01).PubMedPubMedCentralCrossRef Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775–81 (Epub 1997/06/01).PubMedPubMedCentralCrossRef
156.
go back to reference Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(1):21–9 (Epub 2007/06/09).PubMedCrossRef Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(1):21–9 (Epub 2007/06/09).PubMedCrossRef
157.
go back to reference Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005573 (Epub 2007/10/19). Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005573 (Epub 2007/10/19).
158.
go back to reference De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005986 (Epub 2007/10/19). De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):Cd005986 (Epub 2007/10/19).
159.
go back to reference Chande N, McDonald JW, Macdonald JK, et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(10):Cd006774 (Epub 2010/10/12). Chande N, McDonald JW, Macdonald JK, et al. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(10):Cd006774 (Epub 2010/10/12).
160.
go back to reference McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2004;(4):Cd004722 (Epub 2004/10/21). McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2004;(4):Cd004722 (Epub 2004/10/21).
161.
go back to reference Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation—a placebo-controlled study. Aliment Pharmacol Ther. 2013;38(3):264–73 (Epub 2013/06/06).PubMedCrossRef Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation—a placebo-controlled study. Aliment Pharmacol Ther. 2013;38(3):264–73 (Epub 2013/06/06).PubMedCrossRef
162.
go back to reference Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988;10(4):406–9 (Epub 1988/08/01).PubMedCrossRef Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988;10(4):406–9 (Epub 1988/08/01).PubMedCrossRef
163.
go back to reference Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56(2):513–22 (Epub 2010/08/03).PubMedCrossRef Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56(2):513–22 (Epub 2010/08/03).PubMedCrossRef
164.
go back to reference Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–7 (Epub 1998/03/24).PubMedCrossRef Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–7 (Epub 1998/03/24).PubMedCrossRef
165.
go back to reference Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–74 (Epub 2010/01/06).PubMedPubMedCentralCrossRef Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567–74 (Epub 2010/01/06).PubMedPubMedCentralCrossRef
166.
go back to reference Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46(1):46–56 (Epub 2010/09/30).PubMedCrossRef Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46(1):46–56 (Epub 2010/09/30).PubMedCrossRef
167.
go back to reference Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137(6):1934–43.e1-3 (Epub 2009/09/22). Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137(6):1934–43.e1-3 (Epub 2009/09/22).
168.
go back to reference Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ. 1962;2(5302):441–3 (Epub 1962/08/18).PubMedPubMedCentralCrossRef Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ. 1962;2(5302):441–3 (Epub 1962/08/18).PubMedPubMedCentralCrossRef
169.
go back to reference Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87 (Epub 2006/03/15).PubMedCrossRef Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87 (Epub 2006/03/15).PubMedCrossRef
170.
go back to reference Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8(7):571–81 (Epub 2014/02/05).PubMedCrossRef Thorlund K, Druyts E, Mills EJ, et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8(7):571–81 (Epub 2014/02/05).PubMedCrossRef
171.
go back to reference Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–11 (Epub 2014/05/21).PubMedCrossRef Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–11 (Epub 2014/05/21).PubMedCrossRef
172.
go back to reference Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45(Suppl):S139–44 (Epub 2011/10/14).PubMedCrossRef Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45(Suppl):S139–44 (Epub 2011/10/14).PubMedCrossRef
173.
go back to reference Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(1):103–10 (Epub 2006/12/05). Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5(1):103–10 (Epub 2006/12/05).
174.
go back to reference Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2010;32(5):615–27 (Epub 2010/07/16).PubMed Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2010;32(5):615–27 (Epub 2010/07/16).PubMed
175.
go back to reference Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025–31 (Epub 2003/10/01).PubMedCrossRef Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025–31 (Epub 2003/10/01).PubMedCrossRef
176.
go back to reference Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255–62 (Epub 2006/02/18).PubMedPubMedCentralCrossRef Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255–62 (Epub 2006/02/18).PubMedPubMedCentralCrossRef
177.
go back to reference Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28(5):589–97 (Epub 2008/06/14).PubMedCrossRef Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28(5):589–97 (Epub 2008/06/14).PubMedCrossRef
178.
go back to reference Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11 (Epub 2005/06/09).PubMedCrossRef Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11 (Epub 2005/06/09).PubMedCrossRef
179.
go back to reference Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002 (Epub 2003/06/13).PubMedPubMedCentralCrossRef Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002 (Epub 2003/06/13).PubMedPubMedCentralCrossRef
180.
go back to reference Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25(1):19–37 (Epub 2007/01/19).PubMedCrossRef Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25(1):19–37 (Epub 2007/01/19).PubMedCrossRef
181.
go back to reference Huang X, Lv B, Jin HF, et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol. 2011;67(8):759–66 (Epub 2011/06/22).PubMedCrossRef Huang X, Lv B, Jin HF, et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol. 2011;67(8):759–66 (Epub 2011/06/22).PubMedCrossRef
182.
go back to reference Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7 (Epub 2011/01/07).PubMedCrossRef Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7 (Epub 2011/01/07).PubMedCrossRef
183.
go back to reference Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–71 (Epub 2014/02/11).PubMedCrossRef Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660–71 (Epub 2014/02/11).PubMedCrossRef
184.
go back to reference Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27(12):1157–66 (Epub 2008/04/04).PubMedCrossRef Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27(12):1157–66 (Epub 2008/04/04).PubMedCrossRef
185.
go back to reference Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995;7(11):1025–30 (Epub 1995/11/01).PubMedCrossRef Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995;7(11):1025–30 (Epub 1995/11/01).PubMedCrossRef
186.
go back to reference d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92(7):1143–7 (Epub 1997/07/01).PubMed d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92(7):1143–7 (Epub 1997/07/01).PubMed
187.
go back to reference Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13(9):1115–20 (Epub 2007/04/25).PubMedCrossRef Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13(9):1115–20 (Epub 2007/04/25).PubMedCrossRef
188.
go back to reference Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J Clin Gastroenterol. 2002;34(4):397–407 (Epub 2002/03/22).PubMedCrossRef Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J Clin Gastroenterol. 2002;34(4):397–407 (Epub 2002/03/22).PubMedCrossRef
189.
go back to reference Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (Clin Res Ed). 1992;305(6844):20–2 (Epub 1992/07/04).CrossRef Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (Clin Res Ed). 1992;305(6844):20–2 (Epub 1992/07/04).CrossRef
190.
go back to reference Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30(2):126–37 (Epub 2009/04/28).PubMedCrossRef Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30(2):126–37 (Epub 2009/04/28).PubMedCrossRef
191.
go back to reference Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99(6):1122–8 (Epub 2004/06/08).PubMedCrossRef Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99(6):1122–8 (Epub 2004/06/08).PubMedCrossRef
192.
go back to reference Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60 (quiz 520. Epub 2009/07/15).PubMedCrossRef Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60 (quiz 520. Epub 2009/07/15).PubMedCrossRef
193.
go back to reference D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199–212 (quiz 3. Epub 2010/11/04).PubMedCrossRef D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199–212 (quiz 3. Epub 2010/11/04).PubMedCrossRef
194.
go back to reference Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Sur. 2010;97(3):404–9 (Epub 2010/01/27).CrossRef Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Sur. 2010;97(3):404–9 (Epub 2010/01/27).CrossRef
195.
go back to reference Ikeuchi H, Yamamura H, Nakano M, et al. Prognosis following surgery for ulcerative colitis in elderly patients. J Jpn Soc Coloproctol. 2007;60:136–41.CrossRef Ikeuchi H, Yamamura H, Nakano M, et al. Prognosis following surgery for ulcerative colitis in elderly patients. J Jpn Soc Coloproctol. 2007;60:136–41.CrossRef
196.
go back to reference Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33 (Epub 2012/10/09).PubMedCrossRef Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33 (Epub 2012/10/09).PubMedCrossRef
197.
go back to reference Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003;238(3):433–41 (Epub 2003/09/23).PubMedPubMedCentral Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003;238(3):433–41 (Epub 2003/09/23).PubMedPubMedCentral
198.
go back to reference Kirat HT, Remzi FH, Kiran RP, et al. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. Surgery. 2009;146(4):723–9 (discussion 9-30. Epub 2009/10/01).PubMedCrossRef Kirat HT, Remzi FH, Kiran RP, et al. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. Surgery. 2009;146(4):723–9 (discussion 9-30. Epub 2009/10/01).PubMedCrossRef
199.
go back to reference Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009;(1):Cd006267 (Epub 2009/01/23). Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. Cochrane Database Syst Rev. 2009;(1):Cd006267 (Epub 2009/01/23).
200.
go back to reference Surgery JSfE. Guidelines for laparoscopic surgery for inflammatory bowel disease. Practical guidelines for endoscopic surgery. Tokyo: Kanehara & Co., LTD.; 2008. p. 54–64. Surgery JSfE. Guidelines for laparoscopic surgery for inflammatory bowel disease. Practical guidelines for endoscopic surgery. Tokyo: Kanehara & Co., LTD.; 2008. p. 54–64.
201.
go back to reference de Zeeuw S, Ahmed Ali U, Donders RA, et al. Update of complications and functional outcome of the ileo-pouch anal anastomosis: overview of evidence and meta-analysis of 96 observational studies. Int J Colorectal Dis. 2012;27(7):843–53 (Epub 2012/01/10).PubMedPubMedCentralCrossRef de Zeeuw S, Ahmed Ali U, Donders RA, et al. Update of complications and functional outcome of the ileo-pouch anal anastomosis: overview of evidence and meta-analysis of 96 observational studies. Int J Colorectal Dis. 2012;27(7):843–53 (Epub 2012/01/10).PubMedPubMedCentralCrossRef
202.
go back to reference Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg. 2002;235(2):207–16 (Epub 2002/01/25).PubMedPubMedCentralCrossRef Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg. 2002;235(2):207–16 (Epub 2002/01/25).PubMedPubMedCentralCrossRef
203.
go back to reference Ikeuchi H, Uchino M, Matsuoka H, et al. Surgery for ulcerative colitis in 1,000 patients. Int J Colorectal Dis. 2010;25(8):959–65 (Epub 2010/03/11).PubMedCrossRef Ikeuchi H, Uchino M, Matsuoka H, et al. Surgery for ulcerative colitis in 1,000 patients. Int J Colorectal Dis. 2010;25(8):959–65 (Epub 2010/03/11).PubMedCrossRef
204.
go back to reference Munakata A, Hiwatashi N, Muto T, et al. Clinical effects of N-5ASA (oral controlled-release mesalazine) on Crohn’s disease: multicenter, open-label, dose-ranging study. Jpn Pharmacol Ther. 1994;22:S2531–54. Munakata A, Hiwatashi N, Muto T, et al. Clinical effects of N-5ASA (oral controlled-release mesalazine) on Crohn’s disease: multicenter, open-label, dose-ranging study. Jpn Pharmacol Ther. 1994;22:S2531–54.
205.
go back to reference Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104(5):1293–301 (Epub 1993/05/01).PubMedCrossRef Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104(5):1293–301 (Epub 1993/05/01).PubMedCrossRef
206.
go back to reference Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116(3):521–6 (Epub 1999/02/25).PubMedCrossRef Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116(3):521–6 (Epub 1999/02/25).PubMedCrossRef
207.
go back to reference Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):617–29 (Epub 2011/03/17).PubMedCrossRef Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):617–29 (Epub 2011/03/17).PubMedCrossRef
208.
go back to reference Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4(1):28–62 (Epub 2010/12/03).PubMedCrossRef Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4(1):28–62 (Epub 2010/12/03).PubMedCrossRef
209.
go back to reference Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2004;(1):Cd003574 (Epub 2004/02/20). Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2004;(1):Cd003574 (Epub 2004/02/20).
210.
go back to reference Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14(3):348–54.e17 (Epub 2015/06/15). Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14(3):348–54.e17 (Epub 2015/06/15).
211.
go back to reference Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69 (Epub 1979/10/01).PubMed Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69 (Epub 1979/10/01).PubMed
212.
go back to reference Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7 (Epub 1995/02/02).PubMedCrossRef Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7 (Epub 1995/02/02).PubMedCrossRef
213.
go back to reference Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003459 (Epub 2005/01/28). Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):Cd003459 (Epub 2005/01/28).
214.
go back to reference Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35 (Epub 1997/10/09).PubMedCrossRef Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35 (Epub 1997/10/09).PubMedCrossRef
215.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (Lond, Engl). 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRef Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (Lond, Engl). 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRef
216.
go back to reference Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33 (quiz 591. Epub 2006/02/14).PubMedCrossRef Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33 (quiz 591. Epub 2006/02/14).PubMedCrossRef
217.
go back to reference Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65 (Epub 2007/01/24).PubMedCrossRef Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65 (Epub 2007/01/24).PubMedCrossRef
218.
go back to reference Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6(6):644–53 (Epub 2008/06/14). Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6(6):644–53 (Epub 2008/06/14).
219.
go back to reference Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess (Winch, Engl). 2011;15(6):1–244 (Epub 2011/02/05). Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess (Winch, Engl). 2011;15(6):1–244 (Epub 2011/02/05).
220.
go back to reference Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43 (Epub 2001/03/31).PubMedCrossRef Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43 (Epub 2001/03/31).PubMedCrossRef
221.
222.
go back to reference Futami K. Development of therapeutic guidelines for anal lesions of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 53–4. Futami K. Development of therapeutic guidelines for anal lesions of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2013. p. 53–4.
223.
go back to reference Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101 (Epub 2010/12/03).PubMedCrossRef Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101 (Epub 2010/12/03).PubMedCrossRef
224.
go back to reference Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42 (Epub 1995/07/15).PubMedCrossRef Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42 (Epub 1995/07/15).PubMedCrossRef
225.
go back to reference Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980;79(2):357–65 (Epub 1980/08/01).PubMed Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980;79(2):357–65 (Epub 1980/08/01).PubMed
226.
go back to reference Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405 (Epub 1999/05/06).PubMedCrossRef Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405 (Epub 1999/05/06).PubMedCrossRef
227.
go back to reference Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85 (Epub 2004/02/27).PubMedCrossRef Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85 (Epub 2004/02/27).PubMedCrossRef
228.
go back to reference Judge T, Lichtenstein G. Fistulizing Crohn’s disease. Kirsner’s inflammatory bowel diseases. 6th ed. Edinburgh: Saunders; 2004. p. 700–16. Judge T, Lichtenstein G. Fistulizing Crohn’s disease. Kirsner’s inflammatory bowel diseases. 6th ed. Edinburgh: Saunders; 2004. p. 700–16.
229.
go back to reference Keshaw H, Foong KS, Forbes A, et al. Perianal fistulae in Crohn’s disease: current and future approaches to treatment. Inflamm Bowel Dis. 2010;16(5):870–80 (Epub 2009/10/17).PubMedCrossRef Keshaw H, Foong KS, Forbes A, et al. Perianal fistulae in Crohn’s disease: current and future approaches to treatment. Inflamm Bowel Dis. 2010;16(5):870–80 (Epub 2009/10/17).PubMedCrossRef
230.
go back to reference Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther. 2011;33(1):5–22 (Epub 2010/11/19).PubMedCrossRef Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther. 2011;33(1):5–22 (Epub 2010/11/19).PubMedCrossRef
231.
go back to reference Vavricka SR, Rogler G. Fistula treatment: the unresolved challenge. Dig Dis (Basel, Switz). 2010;28(3):556–64 (Epub 2010/10/12).CrossRef Vavricka SR, Rogler G. Fistula treatment: the unresolved challenge. Dig Dis (Basel, Switz). 2010;28(3):556–64 (Epub 2010/10/12).CrossRef
232.
go back to reference Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–9 (Epub 2013/03/26).PubMedCrossRef Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–9 (Epub 2013/03/26).PubMedCrossRef
233.
go back to reference Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014;109(9):1443–9 (Epub 2014/08/06).PubMedCrossRef Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014;109(9):1443–9 (Epub 2014/08/06).PubMedCrossRef
234.
go back to reference Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122(2):512–30 (Epub 2002/02/08).PubMedCrossRef Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122(2):512–30 (Epub 2002/02/08).PubMedCrossRef
235.
go back to reference Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(11–12):1457–64 (Epub 2007/10/02).PubMedCrossRef Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(11–12):1457–64 (Epub 2007/10/02).PubMedCrossRef
236.
go back to reference Ono Y, Hirai F, Matsui T, et al. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2012;24(6):432–8 (Epub 2012/10/20). Ono Y, Hirai F, Matsui T, et al. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2012;24(6):432–8 (Epub 2012/10/20).
237.
go back to reference Honzawa Y, Nakase H, Matsuura M, et al. Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2013;25(5):535–43 (Epub 2013/02/01). Honzawa Y, Nakase H, Matsuura M, et al. Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn’s disease. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2013;25(5):535–43 (Epub 2013/02/01).
238.
go back to reference Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn’s disease: successful control with infliximab. Am J Gastroenterol. 2002;97(12):3210–1 (Epub 2002/12/21).PubMedCrossRef Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn’s disease: successful control with infliximab. Am J Gastroenterol. 2002;97(12):3210–1 (Epub 2002/12/21).PubMedCrossRef
239.
go back to reference Aniwan S, Eakpongpaisit S, Imraporn B, et al. Infliximab stopped severe gastrointestinal bleeding in Crohn’s disease. World J Gastroenterol. 2012;18(21):2730–4 (Epub 2012/06/13).PubMedPubMedCentralCrossRef Aniwan S, Eakpongpaisit S, Imraporn B, et al. Infliximab stopped severe gastrointestinal bleeding in Crohn’s disease. World J Gastroenterol. 2012;18(21):2730–4 (Epub 2012/06/13).PubMedPubMedCentralCrossRef
240.
go back to reference Kim KJ, Han BJ, Yang SK, et al. Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2012;44(9):723–8 (Epub 2012/04/14). Kim KJ, Han BJ, Yang SK, et al. Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2012;44(9):723–8 (Epub 2012/04/14).
241.
go back to reference Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg (Chicago, Ill: 1960). 1976;111(8):901–5 (Epub 1976/08/01).CrossRef Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg (Chicago, Ill: 1960). 1976;111(8):901–5 (Epub 1976/08/01).CrossRef
242.
go back to reference Alla VM, Ojili V, Gorthi J, et al. Revisiting the past: intra-arterial vasopressin for severe gastrointestinal bleeding in Crohn’s disease. J Crohns Colitis. 2010;4(4):479–82 (Epub 2010/12/03).PubMedCrossRef Alla VM, Ojili V, Gorthi J, et al. Revisiting the past: intra-arterial vasopressin for severe gastrointestinal bleeding in Crohn’s disease. J Crohns Colitis. 2010;4(4):479–82 (Epub 2010/12/03).PubMedCrossRef
243.
244.
go back to reference Belaiche J, Louis E, D’Haens G, et al. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroenterol. 1999;94(8):2177–81 (Epub 1999/08/13).PubMedCrossRef Belaiche J, Louis E, D’Haens G, et al. Acute lower gastrointestinal bleeding in Crohn’s disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroenterol. 1999;94(8):2177–81 (Epub 1999/08/13).PubMedCrossRef
245.
go back to reference Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39(5):441–8 (Epub 2004/06/04).PubMedCrossRef Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004;39(5):441–8 (Epub 2004/06/04).PubMedCrossRef
246.
go back to reference Potthast S, Rieber A, Von Tirpitz C, et al. Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison. Eur Radiol. 2002;12(6):1416–22 (Epub 2002/06/04).PubMedCrossRef Potthast S, Rieber A, Von Tirpitz C, et al. Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison. Eur Radiol. 2002;12(6):1416–22 (Epub 2002/06/04).PubMedCrossRef
247.
go back to reference Gervais DA, Hahn PF, O’Neill MJ, et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222(3):645–51 (Epub 2002/02/28).PubMedCrossRef Gervais DA, Hahn PF, O’Neill MJ, et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222(3):645–51 (Epub 2002/02/28).PubMedCrossRef
248.
go back to reference Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn’s disease. Am J Gastroenterol. 2006;101(10):2283–9 (Epub 2006/10/13).PubMedCrossRef Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn’s disease. Am J Gastroenterol. 2006;101(10):2283–9 (Epub 2006/10/13).PubMedCrossRef
249.
go back to reference Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127–36 (Epub 2006/04/14).PubMedCrossRef Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127–36 (Epub 2006/04/14).PubMedCrossRef
250.
go back to reference van Hogezand RA, Witte AM, Veenendaal RA, et al. Proximal Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis. 2001;7(4):328–37 (Epub 2001/11/27).PubMedCrossRef van Hogezand RA, Witte AM, Veenendaal RA, et al. Proximal Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis. 2001;7(4):328–37 (Epub 2001/11/27).PubMedCrossRef
251.
go back to reference Mottet C, Juillerat P, Pittet V, et al. Upper gastrointestinal Crohn’s disease. Digestion. 2007;76(2):136–40 (Epub 2008/02/02).PubMedCrossRef Mottet C, Juillerat P, Pittet V, et al. Upper gastrointestinal Crohn’s disease. Digestion. 2007;76(2):136–40 (Epub 2008/02/02).PubMedCrossRef
252.
go back to reference Ando Y, Matsushita M, Kawamata S, et al. Infliximab for severe gastrointestinal bleeding in Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):483–4 (Epub 2008/08/01).PubMedCrossRef Ando Y, Matsushita M, Kawamata S, et al. Infliximab for severe gastrointestinal bleeding in Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):483–4 (Epub 2008/08/01).PubMedCrossRef
253.
go back to reference Nagamata H, Torii A, Izumi M, et al. A case of Crohn’s disease that shows the improvement of the gastric disorder by the administration of mesalazine powder. Nihon Shokakibyo Gakkai zasshi = Jpn J Gastro-enterol. 2000;97(10):1261–6 (Epub 2000/11/15). Nagamata H, Torii A, Izumi M, et al. A case of Crohn’s disease that shows the improvement of the gastric disorder by the administration of mesalazine powder. Nihon Shokakibyo Gakkai zasshi = Jpn J Gastro-enterol. 2000;97(10):1261–6 (Epub 2000/11/15).
254.
go back to reference Matsui T, Hatakeyama S, Ikeda K, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn’s disease. Endoscopy. 1997;29(7):640–5 (Epub 1997/11/14).PubMedCrossRef Matsui T, Hatakeyama S, Ikeda K, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn’s disease. Endoscopy. 1997;29(7):640–5 (Epub 1997/11/14).PubMedCrossRef
255.
go back to reference Tonelli F, Alemanno G, Bellucci F, et al. Symptomatic duodenal Crohn’s disease: is strictureplasty the right choice? J Crohns Colitis. 2013;7(10):791–6 (Epub 2012/11/21).PubMedCrossRef Tonelli F, Alemanno G, Bellucci F, et al. Symptomatic duodenal Crohn’s disease: is strictureplasty the right choice? J Crohns Colitis. 2013;7(10):791–6 (Epub 2012/11/21).PubMedCrossRef
256.
go back to reference Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn’s disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009;3(4):257–63 (Epub 2010/12/22).PubMedCrossRef Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn’s disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009;3(4):257–63 (Epub 2010/12/22).PubMedCrossRef
257.
go back to reference Magro F, Rodrigues-Pinto E, Coelho R, et al. Is it possible to change phenotype progression in Crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109(7):1026–36 (Epub 2014/05/07).PubMedCrossRef Magro F, Rodrigues-Pinto E, Coelho R, et al. Is it possible to change phenotype progression in Crohn’s disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109(7):1026–36 (Epub 2014/05/07).PubMedCrossRef
258.
go back to reference Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990;98(5 Pt 1):1123–8 (Epub 1990/05/01).PubMedCrossRef Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990;98(5 Pt 1):1123–8 (Epub 1990/05/01).PubMedCrossRef
259.
go back to reference Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481–91 (Epub 2005/09/16).PubMedPubMedCentralCrossRef Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481–91 (Epub 2005/09/16).PubMedPubMedCentralCrossRef
260.
go back to reference Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).PubMedCrossRef Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).PubMedCrossRef
261.
go back to reference Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):Cd000067 (Epub 2000/05/05). Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):Cd000067 (Epub 2000/05/05).
262.
go back to reference Yamamoto T, Nakahigashi M, Saniabadi AR, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).PubMedCrossRef Yamamoto T, Nakahigashi M, Saniabadi AR, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).PubMedCrossRef
263.
go back to reference Keller J, Panter H, Layer P. Management of the short bowel syndrome after extensive small bowel resection. Best Pract Res Clin Gastroenterol. 2004;18(5):977–92 (Epub 2004/10/21).PubMedCrossRef Keller J, Panter H, Layer P. Management of the short bowel syndrome after extensive small bowel resection. Best Pract Res Clin Gastroenterol. 2004;18(5):977–92 (Epub 2004/10/21).PubMedCrossRef
264.
go back to reference Erkelens GW, van Deventer SJ. Endoscopic treatment of strictures in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2004;18(1):201–7 (Epub 2004/05/05).PubMedCrossRef Erkelens GW, van Deventer SJ. Endoscopic treatment of strictures in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2004;18(1):201–7 (Epub 2004/05/05).PubMedCrossRef
265.
go back to reference Feagins LA, Holubar SD, Kane SV, et al. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(10):842–50 (Epub 2011/06/18). Feagins LA, Holubar SD, Kane SV, et al. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(10):842–50 (Epub 2011/06/18).
266.
go back to reference Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224(4):563–71 (discussion 71-3. Epub 1996/10/01).PubMedPubMedCentralCrossRef Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224(4):563–71 (discussion 71-3. Epub 1996/10/01).PubMedPubMedCentralCrossRef
267.
go back to reference Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968–86 (Epub 2007/09/01).PubMedCrossRef Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968–86 (Epub 2007/09/01).PubMedCrossRef
268.
go back to reference Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. Dis Colon Rectum. 2007;50(10):1674–87 (Epub 2007/08/09).PubMedCrossRef Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. Dis Colon Rectum. 2007;50(10):1674–87 (Epub 2007/08/09).PubMedCrossRef
269.
go back to reference McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–27 (Epub 2009/06/09).PubMedCrossRef McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–27 (Epub 2009/06/09).PubMedCrossRef
270.
go back to reference Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2009;13(7):1251–9 (Epub 2009/03/21).CrossRef Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2009;13(7):1251–9 (Epub 2009/03/21).CrossRef
271.
go back to reference Dasari BV, McKay D, Gardiner K. Laparoscopic versus open surgery for small bowel Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd006956 (Epub 2011/01/21). Dasari BV, McKay D, Gardiner K. Laparoscopic versus open surgery for small bowel Crohn’s disease. Cochrane Database Syst Rev. 2011;(1):Cd006956 (Epub 2011/01/21).
272.
go back to reference Shinozaki M. Crohn’s disease and intestinal cancer in Japan. J Jpn Soc Coloproctol. 2008;61:353–63.CrossRef Shinozaki M. Crohn’s disease and intestinal cancer in Japan. J Jpn Soc Coloproctol. 2008;61:353–63.CrossRef
273.
go back to reference Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25(6):665–72 (Epub 1984/06/01).PubMedPubMedCentralCrossRef Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25(6):665–72 (Epub 1984/06/01).PubMedPubMedCentralCrossRef
274.
go back to reference Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).PubMedCrossRef Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).PubMedCrossRef
275.
go back to reference Fukushima T, Sugita A, Baba S, et al. Analysis of factors for postoperative recurrence of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1996. p. 58–60. Fukushima T, Sugita A, Baba S, et al. Analysis of factors for postoperative recurrence of Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 1996. p. 58–60.
276.
go back to reference Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009;(4):Cd006873 (Epub 2009/10/13). Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009;(4):Cd006873 (Epub 2009/10/13).
277.
go back to reference El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311–7 (Epub 2006/02/04).PubMedCrossRef El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311–7 (Epub 2006/02/04).PubMedCrossRef
278.
go back to reference Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(2):203–11 (Epub 2006/02/14). Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(2):203–11 (Epub 2006/02/14).
279.
go back to reference Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273–83 (Epub 2005/07/16).PubMedCrossRef Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273–83 (Epub 2005/07/16).PubMedCrossRef
280.
go back to reference Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–50 (Epub 2011/08/10).PubMedCrossRef Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–50 (Epub 2011/08/10).PubMedCrossRef
281.
go back to reference Ohmori T, Yamagiwa A, Nakamura I, et al. Treatment of pyoderma gangrenosum associated with Crohn’s disease. Am J Gastroenterol. 2003;98(9):2101–2 (Epub 2003/09/23).PubMedCrossRef Ohmori T, Yamagiwa A, Nakamura I, et al. Treatment of pyoderma gangrenosum associated with Crohn’s disease. Am J Gastroenterol. 2003;98(9):2101–2 (Epub 2003/09/23).PubMedCrossRef
282.
go back to reference Fujimoto E, Fujimoto N, Kuroda K, et al. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151(5):1090–2 (Epub 2004/11/16).PubMedCrossRef Fujimoto E, Fujimoto N, Kuroda K, et al. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151(5):1090–2 (Epub 2004/11/16).PubMedCrossRef
283.
go back to reference Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apheresis Dial Off Peer Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Ther. 2007;11(5):387–90 (Epub 2007/09/12).CrossRef Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apheresis Dial Off Peer Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Ther. 2007;11(5):387–90 (Epub 2007/09/12).CrossRef
284.
go back to reference Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9 (Epub 2005/09/29).PubMedPubMedCentralCrossRef Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9 (Epub 2005/09/29).PubMedPubMedCentralCrossRef
285.
go back to reference Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (Lond, Engl). 2002;359(9313):1187–93 (Epub 2002/04/17).CrossRef Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (Lond, Engl). 2002;359(9313):1187–93 (Epub 2002/04/17).CrossRef
286.
go back to reference Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(6):639–45 (Epub 2012/02/01). Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(6):639–45 (Epub 2012/02/01).
287.
go back to reference Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74, 74.e1-4 (quiz e12-3. Epub 2010/02/10). Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74, 74.e1-4 (quiz e12-3. Epub 2010/02/10).
288.
go back to reference Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60 (Epub 2004/01/16).PubMedPubMedCentralCrossRef Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60 (Epub 2004/01/16).PubMedPubMedCentralCrossRef
289.
go back to reference Omata F, Ohde S, Deshpande GA, et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol. 2014;49(2):222–37 (Epub 2013/12/18).PubMedCrossRef Omata F, Ohde S, Deshpande GA, et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol. 2014;49(2):222–37 (Epub 2013/12/18).PubMedCrossRef
290.
go back to reference Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130(4):1039–46 (Epub 2006/04/19).PubMedCrossRef Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130(4):1039–46 (Epub 2006/04/19).PubMedCrossRef
291.
go back to reference Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn’s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28(8):1300–5 (Epub 2013/03/16).PubMedCrossRef Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn’s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28(8):1300–5 (Epub 2013/03/16).PubMedCrossRef
292.
go back to reference Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology. 2001;120(4):820–6 (Epub 2001/03/07).PubMedCrossRef Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology. 2001;120(4):820–6 (Epub 2001/03/07).PubMedCrossRef
293.
go back to reference Sugita A. Clinical characteristics and prognosis of small intestinal and colorectal cancers associated with ulcerative colitis and Crohn’s disease (10th report)—a proposal for the establishment of surveillance program for recto-anal cancer associated with Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2015. Sugita A. Clinical characteristics and prognosis of small intestinal and colorectal cancers associated with ulcerative colitis and Crohn’s disease (10th report)—a proposal for the establishment of surveillance program for recto-anal cancer associated with Crohn’s disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2015.
294.
go back to reference Minakami H, Maeda T, Fujii T, et al. Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition. J Obstet Gynaecol Res. 2014;40(6):1469–99. Minakami H, Maeda T, Fujii T, et al. Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition. J Obstet Gynaecol Res. 2014;40(6):1469–99.
295.
go back to reference Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575–80 (Epub 2006/06/15).PubMedPubMedCentralCrossRef Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575–80 (Epub 2006/06/15).PubMedPubMedCentralCrossRef
296.
go back to reference O’Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25(10):1078–84 (Epub 1984/10/01).PubMedPubMedCentralCrossRef O’Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984;25(10):1078–84 (Epub 1984/10/01).PubMedPubMedCentralCrossRef
297.
go back to reference Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment Pharmacol Ther. 2011;34(7):724–34 (Epub 2011/08/06).PubMedCrossRef Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment Pharmacol Ther. 2011;34(7):724–34 (Epub 2011/08/06).PubMedCrossRef
298.
go back to reference Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17(3):795–801 (Epub 2010/06/22).PubMedCrossRef Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17(3):795–801 (Epub 2010/06/22).PubMedCrossRef
299.
go back to reference van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107–24 (Epub 2015/01/21).PubMedCrossRef van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107–24 (Epub 2015/01/21).PubMedCrossRef
300.
go back to reference Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11(2):116–27 (Epub 2013/07/31).PubMedCrossRef Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11(2):116–27 (Epub 2013/07/31).PubMedCrossRef
301.
go back to reference Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):847–53 (Epub 2013/09/06).PubMedCrossRef Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):847–53 (Epub 2013/09/06).PubMedCrossRef
302.
go back to reference Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohns Colitis. 2011;5(4):317–23 (Epub 2011/06/21).PubMedCrossRef Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohns Colitis. 2011;5(4):317–23 (Epub 2011/06/21).PubMedCrossRef
303.
go back to reference Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210 (Epub 2013/05/28).PubMedPubMedCentralCrossRef Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210 (Epub 2013/05/28).PubMedPubMedCentralCrossRef
304.
go back to reference Sato A, Naganuma M, Asakura K, et al. Conception outcomes and opinions about pregnancy for men with inflammatory bowel disease. J Crohns Colitis. 2010;4(2):183–8 (Epub 2010/12/03).PubMedCrossRef Sato A, Naganuma M, Asakura K, et al. Conception outcomes and opinions about pregnancy for men with inflammatory bowel disease. J Crohns Colitis. 2010;4(2):183–8 (Epub 2010/12/03).PubMedCrossRef
305.
go back to reference Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams & Wilkins; 2012. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams & Wilkins; 2012.
306.
go back to reference Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22 (Epub 2012/03/22).PubMedCrossRef Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22 (Epub 2012/03/22).PubMedCrossRef
307.
go back to reference Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(9):1426–38 (Epub 2013/06/12).PubMedCrossRef Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(9):1426–38 (Epub 2013/06/12).PubMedCrossRef
308.
go back to reference Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118–26 (Epub 2000/07/13).PubMedCrossRef Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118–26 (Epub 2000/07/13).PubMedCrossRef
309.
go back to reference Cheent K, Nolan J, Shariq S, et al. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–5 (Epub 2010/12/03).PubMedCrossRef Cheent K, Nolan J, Shariq S, et al. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–5 (Epub 2010/12/03).PubMedCrossRef
310.
go back to reference Diseases JSfPI. Guideline of vaccination for pediatric transplant recipients and immunocompromised hosts. 2014. Diseases JSfPI. Guideline of vaccination for pediatric transplant recipients and immunocompromised hosts. 2014.
311.
go back to reference Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–23 (Epub 2015/02/06).PubMedCrossRef Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–23 (Epub 2015/02/06).PubMedCrossRef
312.
313.
go back to reference Fujimoto T, Kato J, Nasu J, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol. 2007;19(3):229–35 (Epub 2007/02/16).PubMedCrossRef Fujimoto T, Kato J, Nasu J, et al. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol. 2007;19(3):229–35 (Epub 2007/02/16).PubMedCrossRef
314.
go back to reference Miura S. Research on the current situation of the management of elderly patients with inflammatory bowel disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014. p. 146–51. Miura S. Research on the current situation of the management of elderly patients with inflammatory bowel disease. Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry of Health, Labour and Welfare of Japan, 2014. p. 146–51.
315.
go back to reference Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):30–5 (Epub 2010/10/19). Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):30–5 (Epub 2010/10/19).
316.
go back to reference Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44(1):39–43 (Epub 2013/04/05).PubMedCrossRef Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44(1):39–43 (Epub 2013/04/05).PubMedCrossRef
Metadata
Title
Evidence-based clinical practice guidelines for inflammatory bowel disease
Authors
Katsuyoshi Matsuoka
Taku Kobayashi
Fumiaki Ueno
Toshiyuki Matsui
Fumihito Hirai
Nagamu Inoue
Jun Kato
Kenji Kobayashi
Kiyonori Kobayashi
Kazutaka Koganei
Reiko Kunisaki
Satoshi Motoya
Masakazu Nagahori
Hiroshi Nakase
Fumio Omata
Masayuki Saruta
Toshiaki Watanabe
Toshiaki Tanaka
Takanori Kanai
Yoshinori Noguchi
Ken-ichi Takahashi
Kenji Watanabe
Toshifumi Hibi
Yasuo Suzuki
Mamoru Watanabe
Kentaro Sugano
Tooru Shimosegawa
Publication date
01-03-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-018-1439-1

Other articles of this Issue 3/2018

Journal of Gastroenterology 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.